Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients

G. Paganelli, P. Magnani, F. Zito, E. Villa, F. Sudati, L. Lopalco, C. Rossetti, M. Malcovati, F. Chiolerio, E. Seccamani, A. G. Siccardi, F. Fazio

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

We describe a method to postlabel, in vivo, biotinylated monoclonal antibodies pretargeted onto tumor deposits when most of the non-tumor-bound antibodies have already been cleared as avidin-bound complexes. The application of this principle to tumor detection by immunoscintigraphy was tested in 20 patients with histologically documented cancer and increased circulating carcinoembryonic antigen levels. One mg of biotinylated anti-carcinoembryonic antigen monoclonal antibody (FO23C5) was administered i.v. (first step). After 3 days, 4-6 mg of cold avidin were injected i.v. (second step), followed 48 h later by 0.2-0.3 mg of a biotin derivative labeled with 111In (2-3 mCi) (third step). No evidence of toxicity was observed. Whole body radioactivity distribution was measured in five patients at various intervals postinjection by the conjugate counting technique. Tumors and metastases were detected in 18 of 19 patients (the remaining patient was a true negative) within 3 h after administration of 111In-biotin by planar or single photon emission tomography imaging. At the time of imaging, tumor/blood pool ratio was 5.5 ± 3.2, and tumor/liver ratio was 6.7 ± 3.9. Blood clearance of 111Inbiotin was multiexponential, with the fast component having a t1/2 Ë of 5 ± 3 min. Urinary excretion of radioactivity over 3 h was 63.5 ± 4.9% of the injected dose. Radioactivity at 3 h was 6.5 ± 1.8% in blood, 1.6 ± 0.3% in the kidney, and 2.4 ± 0.6% in the liver. This approach represents an improvement in immunoscintigraphic techniques for tumor localization. The potential use for radioimmunotherapy is discussed.

Original languageEnglish
Pages (from-to)5960-5966
Number of pages7
JournalCancer Research
Volume51
Issue number21
Publication statusPublished - Nov 1 1991

Fingerprint

Carcinoembryonic Antigen
Monoclonal Antibodies
Neoplasms
Radioactivity
Avidin
Biotin
Radioimmunotherapy
Liver
Photons
Tomography
Neoplasm Metastasis
Kidney
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., ... Fazio, F. (1991). Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Research, 51(21), 5960-5966.

Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. / Paganelli, G.; Magnani, P.; Zito, F.; Villa, E.; Sudati, F.; Lopalco, L.; Rossetti, C.; Malcovati, M.; Chiolerio, F.; Seccamani, E.; Siccardi, A. G.; Fazio, F.

In: Cancer Research, Vol. 51, No. 21, 01.11.1991, p. 5960-5966.

Research output: Contribution to journalArticle

Paganelli, G, Magnani, P, Zito, F, Villa, E, Sudati, F, Lopalco, L, Rossetti, C, Malcovati, M, Chiolerio, F, Seccamani, E, Siccardi, AG & Fazio, F 1991, 'Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients', Cancer Research, vol. 51, no. 21, pp. 5960-5966.
Paganelli, G. ; Magnani, P. ; Zito, F. ; Villa, E. ; Sudati, F. ; Lopalco, L. ; Rossetti, C. ; Malcovati, M. ; Chiolerio, F. ; Seccamani, E. ; Siccardi, A. G. ; Fazio, F. / Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. In: Cancer Research. 1991 ; Vol. 51, No. 21. pp. 5960-5966.
@article{04b8bc55b0724494b4c8ce633591e813,
title = "Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients",
abstract = "We describe a method to postlabel, in vivo, biotinylated monoclonal antibodies pretargeted onto tumor deposits when most of the non-tumor-bound antibodies have already been cleared as avidin-bound complexes. The application of this principle to tumor detection by immunoscintigraphy was tested in 20 patients with histologically documented cancer and increased circulating carcinoembryonic antigen levels. One mg of biotinylated anti-carcinoembryonic antigen monoclonal antibody (FO23C5) was administered i.v. (first step). After 3 days, 4-6 mg of cold avidin were injected i.v. (second step), followed 48 h later by 0.2-0.3 mg of a biotin derivative labeled with 111In (2-3 mCi) (third step). No evidence of toxicity was observed. Whole body radioactivity distribution was measured in five patients at various intervals postinjection by the conjugate counting technique. Tumors and metastases were detected in 18 of 19 patients (the remaining patient was a true negative) within 3 h after administration of 111In-biotin by planar or single photon emission tomography imaging. At the time of imaging, tumor/blood pool ratio was 5.5 ± 3.2, and tumor/liver ratio was 6.7 ± 3.9. Blood clearance of 111Inbiotin was multiexponential, with the fast component having a t1/2 {\"E} of 5 ± 3 min. Urinary excretion of radioactivity over 3 h was 63.5 ± 4.9{\%} of the injected dose. Radioactivity at 3 h was 6.5 ± 1.8{\%} in blood, 1.6 ± 0.3{\%} in the kidney, and 2.4 ± 0.6{\%} in the liver. This approach represents an improvement in immunoscintigraphic techniques for tumor localization. The potential use for radioimmunotherapy is discussed.",
author = "G. Paganelli and P. Magnani and F. Zito and E. Villa and F. Sudati and L. Lopalco and C. Rossetti and M. Malcovati and F. Chiolerio and E. Seccamani and Siccardi, {A. G.} and F. Fazio",
year = "1991",
month = "11",
day = "1",
language = "English",
volume = "51",
pages = "5960--5966",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients

AU - Paganelli, G.

AU - Magnani, P.

AU - Zito, F.

AU - Villa, E.

AU - Sudati, F.

AU - Lopalco, L.

AU - Rossetti, C.

AU - Malcovati, M.

AU - Chiolerio, F.

AU - Seccamani, E.

AU - Siccardi, A. G.

AU - Fazio, F.

PY - 1991/11/1

Y1 - 1991/11/1

N2 - We describe a method to postlabel, in vivo, biotinylated monoclonal antibodies pretargeted onto tumor deposits when most of the non-tumor-bound antibodies have already been cleared as avidin-bound complexes. The application of this principle to tumor detection by immunoscintigraphy was tested in 20 patients with histologically documented cancer and increased circulating carcinoembryonic antigen levels. One mg of biotinylated anti-carcinoembryonic antigen monoclonal antibody (FO23C5) was administered i.v. (first step). After 3 days, 4-6 mg of cold avidin were injected i.v. (second step), followed 48 h later by 0.2-0.3 mg of a biotin derivative labeled with 111In (2-3 mCi) (third step). No evidence of toxicity was observed. Whole body radioactivity distribution was measured in five patients at various intervals postinjection by the conjugate counting technique. Tumors and metastases were detected in 18 of 19 patients (the remaining patient was a true negative) within 3 h after administration of 111In-biotin by planar or single photon emission tomography imaging. At the time of imaging, tumor/blood pool ratio was 5.5 ± 3.2, and tumor/liver ratio was 6.7 ± 3.9. Blood clearance of 111Inbiotin was multiexponential, with the fast component having a t1/2 Ë of 5 ± 3 min. Urinary excretion of radioactivity over 3 h was 63.5 ± 4.9% of the injected dose. Radioactivity at 3 h was 6.5 ± 1.8% in blood, 1.6 ± 0.3% in the kidney, and 2.4 ± 0.6% in the liver. This approach represents an improvement in immunoscintigraphic techniques for tumor localization. The potential use for radioimmunotherapy is discussed.

AB - We describe a method to postlabel, in vivo, biotinylated monoclonal antibodies pretargeted onto tumor deposits when most of the non-tumor-bound antibodies have already been cleared as avidin-bound complexes. The application of this principle to tumor detection by immunoscintigraphy was tested in 20 patients with histologically documented cancer and increased circulating carcinoembryonic antigen levels. One mg of biotinylated anti-carcinoembryonic antigen monoclonal antibody (FO23C5) was administered i.v. (first step). After 3 days, 4-6 mg of cold avidin were injected i.v. (second step), followed 48 h later by 0.2-0.3 mg of a biotin derivative labeled with 111In (2-3 mCi) (third step). No evidence of toxicity was observed. Whole body radioactivity distribution was measured in five patients at various intervals postinjection by the conjugate counting technique. Tumors and metastases were detected in 18 of 19 patients (the remaining patient was a true negative) within 3 h after administration of 111In-biotin by planar or single photon emission tomography imaging. At the time of imaging, tumor/blood pool ratio was 5.5 ± 3.2, and tumor/liver ratio was 6.7 ± 3.9. Blood clearance of 111Inbiotin was multiexponential, with the fast component having a t1/2 Ë of 5 ± 3 min. Urinary excretion of radioactivity over 3 h was 63.5 ± 4.9% of the injected dose. Radioactivity at 3 h was 6.5 ± 1.8% in blood, 1.6 ± 0.3% in the kidney, and 2.4 ± 0.6% in the liver. This approach represents an improvement in immunoscintigraphic techniques for tumor localization. The potential use for radioimmunotherapy is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026356523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026356523&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 5960

EP - 5966

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -